Resource Center

Press Release – June 13, 2025

Panavance Therapeutics Announces Promising Misetionamide (GP-2250) Phase 1 Clinical Trial Interim Findings in Pancreatic Cancer at BIO 2025

Read Release

poster

Interim Open-Label Phase 1 Results of Misetionamide (GP-2250): A Small Molecule Antineoplastic That Inhibits Three Major Transcription Factors

Press Release – November 19, 2024

Panavance Announces New Discovery that Misetionamide Directly Inhibits Oncogenic Transcription Factor c-MYC

Read Release

Press Release – October 9, 2024

Panavance Therapeutics Provides Update on Phase 1 Clinical Trial of Misetionamide in Pancreatic Cancer at 2024 Visceral Medicine Congress

Read Release

Press Release – August 14, 2024

Panavance Therapeutics Announces Foundational Publication of Misetionamide (GP-2250) in Ovarian Cancer in the Journal, Cancer Medicine

Read Release

publication

Publication Summary – Misetionamide (GP-2250)

A summary of all publications with links to full document

publication

Mechanisms and rational combinations with GP-2250, novel oxathiazine derivative in ovarian cancer.

Mark Kim, Deanna Glassman, Katelyn F Handley, Adrian Lankenau ahumada, Emine Bayraktar, Nicholas B. Jennings, Robiya Joseph, Robert L. Coleman and Anil K. Sood.

publication

Antineoplastic activity of GP-2250 in-vitro and in mouse xenograft models

R. Duane Soﬁa, Kathryn M. Martin and James C. Costin

publication

Increasing the cytotoxic effectivity of 5FU, Irinotecan and Oxaliplatin on pancreatic cancer cells through combination with the novel anticancer agent GP-2250 in vitro

I.Peters; B. Majchrzak-Stiller ; M. Buchholz ; P. Höhn ; W. Uhl ; C. Braumann ; J. Strotmann

Press Release – February 1, 2024

Anti-Cancer Drugs Publishes Preclinical Data Demonstrating the Broad Antineoplastic Activity of Panavance’s Misetionamide (GP-2250)

Read Release

publication

GP- 2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP- Kinase and impairs the NF- kB pathway in pancreatic cancer cells

Britta Majchrzak- Stiller, Marie Buchholz, Ilka Peters, Daniel Waschestjuk, Johanna Strotmann, Philipp Höhn, Stephan Hahn, Chris Braumann, Waldemar Uhl, Thomas Müller, Hanns Möhler

publication

Oxathiazinane Derivatives Display Both Anticancer and Antibacterial Activity: A Structure Activity Study

B. Majchrzak Stiller, M. Buchholz, I. Peters, J. Strotmann, J. Möhrke, L. Zelichowski, L. Oehlke, C. Quensel, D. Fein, P. Höhn, T. Müller, W. Uhl, C. Braumann May 12, 2023

publication

An In Vitro Pilot Study Investigating the Antineoplastic Effects of GP-2250 on Cutaneous Squamous Cell Carcinoma Cell Lines: Preliminary Results

Milan Barras, Lutz Schmitz, Chris Braumann, Waldemar Uhl, Marina Skrygan, Marie Buchholz, Thomas Meyer, Eggert Stockfleth, Thomas Müller, Jürgen C. Becker and Thilo Gambichler

Press Release – November 21, 2023

International Journal of Molecular Sciences Publishes Preclinical Data of Panavance’s Misetionamide (GP-2250) in Melanoma

Read Release

publication

The effect of GP-2250 on cultured virus-negative Merkel cell carcinoma cells: preliminary results

Thilo Gambichler, Britta Majchrzak-Stiller, Ilka Peters, Jürgen C Becker, Johanna Strotmann, Nessr Abu Rached, Thomas Müller, Waldemar Uhl 2, Marie Buchholz, Chris Braumann

publication

Mechanisms and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer

American Association for Cancer Research (AACR) Annual Meeting 2023

Mark S. Kim, Deanna Glassman, Adrian Lankenau Ahumada, Emine Bayraktar, Nicholas B. Jennings, Robiya Joseph, Sanghoon Lee, Robert L. Coleman, Anil K. Sood

publication

In Vitro Experiments on the Effects of GP-2250 on BRAF-Mutated Melanoma Cell Lines and Benign Melanocytes

Thilo Gambichler , Friederike Harnischfeger , Marina Skrygan , Britta Majchrzak-Stiller , Marie Buchholz , Thomas Müller and Chris Braumann

Press Release – October 5, 2023

Panavance to Present at the BIO Investor Forum

Read Release

Press Release – September 12, 2023

Journal of Cellular and Molecular Medicine Publishes Preclinical Data of Panavance’s GP-2250 to treat Pancreatic Cancer

Read Release

event

Panavance Therapeutics to Participate in the Virtual Investor Summer Spotlight Series

Live moderated video webcast on Thursday, July 13th at 2:00 PM ET

Press Release – July 5, 2023

Panavance Therapeutics to Participate in the Virtual Investor Summer Spotlight Series

Read Release

Press Release – June 29, 2023

Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Merkel Cell Carcinoma (MCC)

Read Release

Press Release – May 24, 2023

Panavance Therapeutics to Present at the Biotechnology Innovation Organization (BIO) International Convention

Read Release

Press Release – April 17, 2023

Panavance Therapeutics Announces Positive Preclinical Data Demonstrating GP-2250 Single-Agent and Combination Activity for the Treatment of Ovarian Cancer

Read Release

Press Release – April 12, 2023

Panavance Therapeutics to Present at the BioNJ Annual BioPartnering Conference

Read Release

Press Release – March 20, 2023

Panavance Therapeutics Announces Acceptance of Abstract to be Presented at
the American Association for Cancer Research (AACR) Annual Meeting 2023

Read Release

event

Panavance Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event

Live video webcast on Wednesday, January 18th at 1:00 PM ET

Press Release – January 5, 2023

Panavance Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event

Read Release

event

Panavance Leadership Team participation in the Virtual Investor Innovations in Oncology Event

Greg Bosch, Chairman and CEO of Panavance Therapeutics along with other members of the Panavance Leadership Team participated in the Virtual Investor Innovations in Oncology Spotlight Event. As part of the virtual roundtable event, the Company discussed its lead program, GP-2250, a tumor cell selective and broadly active small molecule with a unique mechanism of action designed to disrupt energy metabolism, resulting in cancer cell death.

Press Release – December 5, 2022

Panavance Therapeutics to Participate at the Virtual Investor Innovations in Oncology Spotlight Event

Read Release

Press Release – November 14, 2022

Panavance Therapeutics to Present at the Pharma Partnering US Summit 2022

Read Release

Press Release – November 2, 2022

Panavance Therapeutics to Present at BioFuture 2022

Read Release

Press Release – August 8, 2022

Panavance Therapeutics Announces Publication of Promising Preclinical Data Evaluating GP-2250 for the Treatment of Malignant Peritoneal Mesothelioma

Read Release

Press Release – June 28, 2022

Panavance Therapeutics Announces Orphan Drug Designation for GP-2250 for the Treatment of Pancreatic Cancer

Read Release

publication

Substance GP-2250 as a new therapeutic agent for malignant peritoneal mesothelioma – a 3-D in vitro study

Claudia Baron, Marie Buchholz, Britta Majchrzak-Stiller, Ilka Peters, Daniel Fein, Thomas Müller, Waldemar Uhl, Philipp Höhn, Johanna Strotmann and Chris Braumann

publication

A phase 1/2 study to evaluate the safety, tolerability, and preliminary efficacy of GP-2250 in combination with gemcitabine for advanced or metastatic pancreatic adenocarcinoma.

A. Kasi, J. L. Iglesias.

publication

New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo

Marie Buchholz, Johanna Strotmann, Britta Majchrzak-Stiller, Stephan Hahn 2, Ilka Peters, Julian Horn Thomas Müller, Philipp Höhn, Waldemar Uhl and Chris Braumann

Press Release – June 9, 2022

Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Pancreatic Neuroendocrine Carcinoma

Read Release

video

Mechanism of Action Explainer Video

While cancer therapies are becoming increasingly specific to tumor and mutation type, a tumor and mutation agnostic yet targeted agent is of high therapeutic utility. Learn about GP-2250’s unique mechanism of action, which kills cancer cells by disrupting their energy metabolism.

Watch Video

brochure

New hope begins with novel science.

Panavance’s purpose is to give every patient the best possible chance to live a healthy and cancer-free life.

publication

Metabolism-based GP-2250 in combination with gemcitabine as a novel approach to pancreatic cancer: A mouse xenograft study- in vitro and in vivo. Journal of Clinical Oncology Vol. 28, No. 15-suppl. May 2020

C. Braumann, M. Buchholz, B. Majchrzak – Stiller, S. Hahn, W. Uhl, A. Kasi, T. Mueller.)

Press Release – January 19, 2022

Panavance Announces Abstract and Poster at ASCO Gastrointestinal Cancers Symposium, Providing an Update on the Status of GP-2250 Clinical Trial in Pancreatic Cancer Patients

Read Release

publication

Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma- in vitro and in vivo.

M. Buchholz, B. Majchrzak-Stiller, S. Hahn, D. Vangala, R. W. Pfirrmann, W. Uhl, C. Braumann and A. M. Chromik.

publication

Innovative substance 2250, a derivative of taurultam, shows anti-neoplastic effects in malignant pancreatic carcinoma in vitro and in vivo

M. Buchholz, B. Majchrzak-Stiller, S. Hahn, R.W. Pfirrmann, A.M. Chromik, W. Uhl.

Press Release – June 13, 2025

Panavance Therapeutics Announces Promising Misetionamide (GP-2250) Phase 1 Clinical Trial Interim Findings in Pancreatic Cancer at BIO 2025

poster

Interim Open-Label Phase 1 Results of Misetionamide (GP-2250): A Small Molecule Antineoplastic That Inhibits Three Major Transcription Factors

Press Release – November 19, 2024

Panavance Announces New Discovery that Misetionamide Directly Inhibits Oncogenic Transcription Factor c-MYC

Press Release – October 9, 2024

Panavance Therapeutics Provides Update on Phase 1 Clinical Trial of Misetionamide in Pancreatic Cancer at 2024 Visceral Medicine Congress

Press Release – August 14, 2024

Panavance Therapeutics Announces Foundational Publication of Misetionamide (GP-2250) in Ovarian Cancer in the Journal, Cancer Medicine

publication

Publication Summary – Misetionamide (GP-2250)

publication

Mechanisms and rational combinations with GP-2250, novel oxathiazine derivative in ovarian cancer.

publication

Antineoplastic activity of GP-2250 in-vitro and in mouse xenograft models

publication

Increasing the cytotoxic effectivity of 5FU, Irinotecan and Oxaliplatin on pancreatic cancer cells through combination with the novel anticancer agent GP-2250 in vitro

Press Release – February 1, 2024

Anti-Cancer Drugs Publishes Preclinical Data Demonstrating the Broad Antineoplastic Activity of Panavance’s Misetionamide (GP-2250)

publication

GP- 2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP- Kinase and impairs the NF- kB pathway in pancreatic cancer cells

publication

Oxathiazinane Derivatives Display Both Anticancer and Antibacterial Activity: A Structure Activity Study

publication

An In Vitro Pilot Study Investigating the Antineoplastic Effects of GP-2250 on Cutaneous Squamous Cell Carcinoma Cell Lines: Preliminary Results

Press Release – November 21, 2023

International Journal of Molecular Sciences Publishes Preclinical Data of Panavance’s Misetionamide (GP-2250) in Melanoma

publication

The effect of GP-2250 on cultured virus-negative Merkel cell carcinoma cells: preliminary results

publication

Mechanisms and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer

publication

In Vitro Experiments on the Effects of GP-2250 on BRAF-Mutated Melanoma Cell Lines and Benign Melanocytes

Press Release – October 5, 2023

Panavance to Present at the BIO Investor Forum

Press Release – September 12, 2023

Journal of Cellular and Molecular Medicine Publishes Preclinical Data of Panavance’s GP-2250 to treat Pancreatic Cancer

event

Panavance Therapeutics to Participate in the Virtual Investor Summer Spotlight Series

Press Release – July 5, 2023

Panavance Therapeutics to Participate in the Virtual Investor Summer Spotlight Series

Press Release – June 29, 2023

Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Merkel Cell Carcinoma (MCC)

Press Release – May 24, 2023

Panavance Therapeutics to Present at the Biotechnology Innovation Organization (BIO) International Convention

Press Release – April 17, 2023

Panavance Therapeutics Announces Positive Preclinical Data Demonstrating GP-2250 Single-Agent and Combination Activity for the Treatment of Ovarian Cancer

Press Release – April 12, 2023

Panavance Therapeutics to Present at the BioNJ Annual BioPartnering Conference

Press Release – March 20, 2023

Panavance Therapeutics Announces Acceptance of Abstract to be Presented atthe American Association for Cancer Research (AACR) Annual Meeting 2023

event

Panavance Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event

Press Release – January 5, 2023

Panavance Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event

event

Panavance Leadership Team participation in the Virtual Investor Innovations in Oncology Event

Press Release – December 5, 2022

Panavance Therapeutics to Participate at the Virtual Investor Innovations in Oncology Spotlight Event

Press Release – November 14, 2022

Panavance Therapeutics to Present at the Pharma Partnering US Summit 2022

Press Release – November 2, 2022

Panavance Therapeutics to Present at BioFuture 2022

Press Release – August 8, 2022

Panavance Therapeutics Announces Publication of Promising Preclinical Data Evaluating GP-2250 for the Treatment of Malignant Peritoneal Mesothelioma

Press Release – June 28, 2022

Panavance Therapeutics Announces Orphan Drug Designation for GP-2250 for the Treatment of Pancreatic Cancer

publication

Substance GP-2250 as a new therapeutic agent for malignant peritoneal mesothelioma – a 3-D in vitro study

publication

A phase 1/2 study to evaluate the safety, tolerability, and preliminary efficacy of GP-2250 in combination with gemcitabine for advanced or metastatic pancreatic adenocarcinoma.

publication

New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo

Press Release – June 9, 2022

Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Pancreatic Neuroendocrine Carcinoma

video

Mechanism of Action Explainer Video

brochure

Panavance Therapeutics Announces Acceptance of Abstract to be Presented at
the American Association for Cancer Research (AACR) Annual Meeting 2023